var data={"title":"Mitoxantrone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mitoxantrone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6596?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mitoxantrone-drug-information\" class=\"drug drug_general\">see &quot;Mitoxantrone: Drug information&quot;</a> and <a href=\"topic.htm?path=mitoxantrone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mitoxantrone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709094\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Mitoxantrone should be administered under the supervision of a health care provider experienced in the use of cytotoxic chemotherapy agents.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Except for the treatment of acute nonlymphocytic leukemia, mitoxantrone therapy generally should not be given to patients with baseline neutrophil counts of less than 1,500 cells/mm<sup>3</sup>. In order to monitor the occurrence of bone marrow suppression (primarily neutropenia, which may be severe and result in infection), it is recommended that frequent peripheral blood cell counts be performed on all patients receiving mitoxantrone.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Congestive heart failure (CHF), potentially fatal, may occur during therapy with mitoxantrone or months to years after termination of therapy. Cardiotoxicity risk increases with cumulative mitoxantrone dose and may occur whether or not cardiac risk factors are present. Presence or history of cardiovascular disease, radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or use of other cardiotoxic drugs may increase this risk. In patients with cancer, the risk of symptomatic CHF was estimated to be 2.6% for patients receiving up to a cumulative dose of 140 mg/m<sup>2</sup>. To mitigate the cardiotoxicity risk with mitoxantrone, consider the following:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">All patients should be assessed for cardiac signs and symptoms by history, physical examination, and electrocardiogram (ECG) prior to start of mitoxantrone therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">All patients should have baseline quantitative evaluation of left ventricular ejection fraction (LVEF) using appropriate methodology (eg, echocardiogram, multigated radionuclide angiogram [MUGA], magnetic resonance imaging [MRI]).</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Patients with multiple sclerosis (MS) with a baseline LVEF below the lower limit of normal should not be treated with mitoxantrone.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Patients with MS should be assessed for cardiac signs and symptoms by history, physical examination, and ECG prior to each dose.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Patients with MS should undergo quantitative reevaluation of LVEF prior to each dose using the same methodology that was used to assess baseline LVEF. Additional doses of mitoxantrone should not be administered to MS patients who have experienced a drop in LVEF to below the lower limit of normal or a clinically significant reduction in LVEF during mitoxantrone therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Patients with MS should not receive a cumulative mitoxantrone dose higher than 140 mg/m<sup>2</sup>.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Patients with MS should undergo yearly quantitative LVEF evaluation after stopping mitoxantrone to monitor for late-occurring cardiotoxicity.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Secondary leukemia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Mitoxantrone therapy in MS patients and in patients with cancer increases the risk of developing secondary acute myeloid leukemia (AML).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate administration:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Mitoxantrone should be given slowly into a freely flowing intravenous (IV) infusion. It must never be given subcutaneously, intramuscularly (IM), or intra-arterially. Severe local tissue damage may occur if there is extravasation during administration. Not for intrathecal use. Severe injury with permanent sequelae can result from intrathecal administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197570\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Mitoxantrone Injection;</li>\n      <li>Mitoxantrone Injection USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048715\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Anthracenedione</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antibiotic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Topoisomerase II Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048707\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=mitoxantrone-drug-information\" class=\"drug drug_general\">see &quot;Mitoxantrone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing regimens may vary by dose, cycles, and combination therapy; refer to individual protocols. Mitoxantrone is associated with a low emetic potential (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphocytic leukemia (ALL), relapsed:</b> Limited data available: Children and Adolescents: Induction: 10 mg/m<sup>2</sup>/dose once daily for 2 days (in combination with other chemotherapeutic agents) (Parker 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia (AML):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Gamis 2014</i>: Infants, Children, and Adolescents: <b>Note:</b> Some aspects of protocol dosing presented in previous reports (Cooper 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intensification Course 2:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA &lt;0.6 m<sup>2</sup>: IV: 0.4 mg/<b>kg</b> once daily for 4 days on Days 3 to 6 of a 28-day cycle (in combination with cytarabine)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA &ge;0.6 m<sup>2</sup>: IV: 12 mg/m<sup>2</sup> once daily for 4 days on Days 3 to 6 of a 28-day cycle (in combination with cytarabine)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Perel 2002</i>: LAME 89/91 regimen: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Remission Induction:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;1 year: IV: 8 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine); if persistent disease, additional course of 8 mg/m<sup>2</sup> for 2 days (in combination with cytarabine) was administered</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;1 year: IV: 12 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine); if persistent disease, additional course of 12 mg/m<sup>2</sup> for 2 days (in combination with cytarabine) was administered</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Gibson 2011: </i>MAE combination:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction Course 1 (MAE 3+10+5) or Course 2 (MAE 3+8+5):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants: IV: 9 mg/m<sup>2</sup> once daily on Days 1, 3, and 5 (in combination with cytarabine and etoposide)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &lt;17 years: IV: 12 mg/m<sup>2</sup> once daily on Days 1, 3, and 5 (in combination with cytarabine and etoposide)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Consolidation Course 4/5 (MidAC):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants: IV: 7.5 mg/m<sup>2</sup> once daily on Days 1 to 5 (in combination with cytarabine)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &lt;17 years: IV: 10 mg/m<sup>2</sup> once daily on Days 1 to 5 (in combination with cytarabine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute promyelocytic leukemia (APL):</b> Limited data available: Consolidation Course 2: Children &ge;2 years and Adolescents: IV: 10 mg/m<sup>2</sup> once daily for 5 days of a 28-day cycle (combined with tretinoin [ATRA]) (Ortega 2005; Sanz 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute nonlymphocytic leukemias (ANLL):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AML induction: 12 mg/m<sup>2</sup> once daily for 3 days (in combination with cytarabine); for incomplete response, may repeat 7 to 10 days later at 12 mg/m<sup>2</sup>/dose once daily for 2 days (Arlin 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AML consolidation (beginning ~6 weeks after initiation of the final induction course): 12 mg/m<sup>2</sup>/dose once daily for 2 days (in combination with cytarabine), repeat in 4 weeks (Arlin 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multiple sclerosis:</b> 12 mg/m<sup>2</sup>/dose every 3 months; maximum lifetime cumulative dose: 140 mg/m<sup>2</sup> (discontinue use with LVEF &lt;50% or clinically significant reduction in LVEF)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prostate cancer (advanced hormone-refractory):</b> 12 to 14 mg/m<sup>2</sup>/dose every 3 weeks (in combination with corticosteroids)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis: Supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, clearance is reduced in hepatic dysfunction. Patients with severe hepatic dysfunction (bilirubin &gt;3.4 mg/dL) have an AUC of 3 times greater than patients with normal hepatic function; consider dose adjustments. <b>Note:</b> MS patients with hepatic impairment should not receive mitoxantrone.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oncology uses: Severe or life-threatening nonhematologic toxicity: Withhold treatment until toxicity resolves</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Multiple sclerosis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Neutrophils &lt;1,500/mm<sup>3</sup>: Use is not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Signs/symptoms of HF: Evaluate for cardiac signs/symptoms and LVEF</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">LVEF &lt;50% or baseline LVEF below the lower limit of normal (LLN): Use is not recommended</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197544\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/10 mL (10 mL); 25 mg/12.5 mL (12.5 mL); 30 mg/15 mL (15 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197529\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13934999\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM297876.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68x8FWowpJdF1ZpcexrI9fSA==&amp;TOPIC_ID=12617\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM297876.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048719\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: For IV administration only; do not administer by SubQ, IM, intrathecal, or intra-arterial injection. Must be diluted prior to use; may administer by IV bolus over 5 to 15 minutes or IV intermittent infusion over 15 to 60 minutes. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Irritant  with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dimethyl sulfate [DMSO] <b>or</b> dexrazoxane [Adults]) (see Management of Drug Extravasations for more details). Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (P&eacute;rez Fidalgo 2012); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132772\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197562\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); do not freeze. Opened vials may be stored at room temperature for 7 days or under refrigeration for up to 14 days. Solutions diluted in D5W or NS for administration are stable for 7 days at room temperature or under refrigeration, although the manufacturer recommends immediate use. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048718\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of acute nonlymphocytic leukemias (ANLL; includes myelogenous, promyelocytic, monocytic, and erythroid leukemias); advanced hormone-refractory prostate cancer, secondary progressive, or relapsing-remitting multiple sclerosis (MS) (All indications: FDA approved in adults); has also been used for relapsed acute lymphocytic leukemia (ALL), pediatric acute myelogenous leukemia (AML), and pediatric acute promyelocytic leukemia (APL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197627\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MitoXANTRONE may be confused with methotrexate, mitoMYcin, mitotane, Mutamycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197623\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, cardiac disease, cardiac failure, decreased left ventricular ejection fraction, ECG changes, edema, hypertension, ischemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, chills, depression, fatigue, headache, pain, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, diaphoresis, nail bed changes, skin infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Amenorrhea, hyperglycemia, hypermenorrhea, hypocalcemia, hypokalemia, hyponatremia, increased gamma-glutamyl transferase, menstrual disease, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, aphthous stomatitis, constipation, diarrhea, dyspepsia, gastrointestinal hemorrhage, mucositis (onset: &le;1 week), nausea, stomatitis (onset: &le;1 week), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria, impotence, proteinuria, sterility, urinary tract infection, urine abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Acute leukemia (secondary; includes AML, APL), anemia, bruise, decreased hemoglobin, febrile neutropenia, granulocytopenia, hemorrhage, leukopenia, lymphocytopenia, neutropenia (onset: &le;3 weeks), petechia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum transaminases, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Fungal infection, fungal infection (cutaneous), infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, pharyngitis, pneumonia, rhinitis, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylactoid reaction, anaphylaxis, chest pain, dehydration, hypersensitivity reaction, interstitial pneumonitis (with combination chemotherapy), hyperuricemia, hypotension, ocular discoloration (blue discoloration of sclera), phlebitis (at infusion site), skin rash, tachycardia, urine discoloration (blue-green), urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197550\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to mitoxantrone or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Prior hypersensitivity to anthracyclines; prior substantial anthracycline exposure and abnormal cardiac function prior to initiation of mitoxantrone therapy; presence of severe myelosuppression due to prior chemo- and/or radiotherapy; severe hepatic impairment; intrathecal administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197533\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: Treatment may lead to severe myelosuppression; unless the expected benefit outweighs the risk, use is generally not recommended in patients with pre-existing myelosuppression from prior chemotherapy. <b>[U.S. Boxed Warning]: Usually should not be administered if baseline neutrophil count &lt;1500 cells/mm<sup>3</sup> (except for in the treatment of ANLL). Monitor blood counts and monitor for infection due to neutropenia.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extravasation: Irritant with vesicant-like properties. <b>[U.S. Boxed Warning]: For IV administration only, into a free-flowing IV; may cause severe local tissue damage if extravasation occurs. </b>Extravasation resulting in burning, erythema, pain, swelling and skin discoloration (blue) has been reported; may result in tissue necrosis and require debridement for skin graft. Ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperuricemia: Rapid lysis of tumor cells may lead to hyperuricemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myocardial toxicity: <b>[U.S. Boxed Warning]: May cause myocardial toxicity and potentially-fatal heart failure (HF); risk increases with cumulative dosing. Effects may occur during therapy or may be delayed (months or years after completion of therapy). Predisposing factors for mitoxantrone-induced cardiotoxicity include prior anthracycline or anthracenedione therapy, prior cardiovascular disease, concomitant use of cardiotoxic drugs, and mediastinal/pericardial irradiation, although may also occur in patients without risk factors. Prior to therapy initiation, evaluate all patients for cardiac-related signs/symptoms, including history, physical exam, and ECG; and evaluate baseline left ventricular ejection fraction (LVEF) with echocardiogram or multigated radionuclide angiography (MUGA) or MRI. Not recommended for use in MS patients when LVEF &lt;50%, or baseline LVEF below the lower limit of normal (LLN). Evaluate for cardiac signs/symptoms (by history, physical exam, and ECG) and evaluate LVEF (using same method as baseline LVEF) in MS patients prior to each dose and if signs/symptoms of HF develop. Use in MS should be limited to a cumulative dose of &le;140 mg/m<sup>2</sup>, and discontinued if LVEF falls below LLN or a significant decrease in LVEF is observed; decreases in LVEF and HF have been observed in patients with MS who have received cumulative doses &lt;100 mg/m<sup>2</sup>. Patients with MS should undergo annual LVEF evaluation following discontinuation of therapy to monitor for delayed cardiotoxicity. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Secondary malignancy: <b>[U.S. Boxed Warning]: Treatment with mitoxantrone increases the risk of developing secondary acute myelogenous leukemia (AML) in patients with cancer and in patients with MS;</b> acute promyelocytic leukemia (APL) has also been observed. Symptoms of acute leukemia include excessive bruising, bleeding and recurrent infections. The risk for secondary leukemia is increased in patients who are heavily pretreated, with higher doses, and with combination chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Clearance is reduced in patients with hepatic impairment; use with caution; dosage adjustment recommended. Not for treatment of multiple sclerosis in patients with concurrent hepatic impairment. Canadian labeling contraindicates use in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Multiple sclerosis: Not for treatment of primary progressive multiple sclerosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate administration: <b>[U.S. Boxed Warning]: For IV administration only, into a free-flowing IV; do not administer subcutaneously, intramuscularly, or intra-arterially. Do not administer intrathecally; may cause serious and permanent neurologic damage.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blue-green coloration: May cause urine, saliva, tears, and sweat to turn blue-green for 24 hours postinfusion; whites of eyes may have blue-green tinge. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: <b>[U.S. Boxed Warning]: Should be administered under the supervision of a physician experienced in cancer chemotherapy agents.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197613\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197538\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12617&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of MitoXANTRONE. Management: Consider mitoxantrone dose reduction, as clinically appropriate, when used with cyclosporine. Use this combination with caution and monitor closely for toxic effects of mitoxantrone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197540\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197553\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Based on the mechanism of action, mitoxantrone may cause fetal harm if administered during pregnancy. Use of effective contraception during therapy is recommended. Information related to pregnancy outcomes following maternal use of mitoxantrone in pregnancy is limited (Amato 2015; Houtchens 2013; NTP 2013). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Infertility and amenorrhea have been reported in women with MS using mitoxantrone (Amato 2015; Houtchens 2013). Women with multiple sclerosis who are of reproductive potential should have a pregnancy test prior to each dose. Women who wish to become pregnant should discontinue therapy at least 2 to 3 months prior to conception (Houtchens 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (Peccatori 2013). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048714\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, platelet count, serum uric acid (for leukemia treatment), liver function tests, women with multiple sclerosis of childbearing potential must have a pregnancy test prior to each dose; injection site for signs of extravasation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Cardiac monitoring:</i> Prior to initiation, evaluate all patients for cardiac-related signs/symptoms, including history, physical exam, and echocardiogram; evaluate baseline and periodic left ventricular ejection fraction (LVEF) with ECG or multigated radionuclide angiography (MUGA) or MRI. In patients with MS, evaluate for cardiac signs/symptoms (by history, physical exam, and ECG) and evaluate LVEF (using same method as baseline LVEF) prior to each dose and if signs/symptoms of HF develop. Patients with MS should undergo annual LVEF evaluation following discontinuation of therapy to monitor for delayed cardiotoxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197532\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Related to the anthracyclines, mitoxantrone intercalates into DNA resulting in cross-links and strand breaks; binds to nucleic acids and inhibits DNA and RNA synthesis by template disordering and steric obstruction; replication is decreased by binding to DNA topoisomerase II and seems to inhibit the incorporation of uridine into RNA and thymidine into DNA; active throughout entire cell cycle (cell-cycle nonspecific)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197549\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Poor </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 14 L/kg; V<sub>dss</sub>: &gt;1,000 L/m<sup>2</sup>; distributes extensively into pleural fluid, kidney, thyroid, liver, heart, pancreas, spleen, bone marrow, and red blood cells; prolonged retention in tissues</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 78% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; pathway not determined </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: 23 to 215 hours (median: ~75 hours); may be prolonged with hepatic impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (25%); urine (6% to 11%; 65% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323431\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (MitoXANTRONE HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/10 mL (10 mL): $303.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/12.5 mL (12.5 mL): $324.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/15 mL (15 mL): $409.42</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197555\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bluxantron (EC);</li>\n      <li>Bresnix (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Domitrone (PH);</li>\n      <li>Ebexantron (SG);</li>\n      <li>Elsep (FR);</li>\n      <li>Evomixan (BR);</li>\n      <li>Formyxan (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Heng En (CN);</li>\n      <li>Mi Xi Ning (CN);</li>\n      <li>Misostol (PY, VE);</li>\n      <li>Mitoxgen (AR, MX);</li>\n      <li>Mitroxone (MX);</li>\n      <li>Mittrone (KR);</li>\n      <li>Neotalem (CL, CO, TH);</li>\n      <li>Novantron (AT, CH, DE);</li>\n      <li>Novantrone (AE, BE, CN, DK, EG, ES, FI, FR, GB, GR, HR, HU, IL, IT, JO, JP, KW, LU, NL, NO, NZ, PK, PL, PT, RO, RU, SA, SE, TR, TW, VN);</li>\n      <li>Oncotron (IN);</li>\n      <li>Oncotrone (BG);</li>\n      <li>Onkotron (UA);</li>\n      <li>Onkotrone (AU, EE, HU, LT, LV, NZ, RO, SI, SK);</li>\n      <li>Refador (CZ);</li>\n      <li>Santrone (HK);</li>\n      <li>Strimax (MT);</li>\n      <li>Vizksantron (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. <i>CNS Drugs</i>. 2015;29(3):207-220.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/25773609 /pubmed\" target=\"_blank\" id=\"25773609 \">25773609 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aplenc R, Alonzo TA, Gerbing RB, et al, &quot;Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group,&quot; <i>J Clin Oncol</i>, 2008, 26(14):2390-3295.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/18467731/pubmed\" target=\"_blank\" id=\"18467731\">18467731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arlin Z, Case DC Jr, Moore J, et al, &quot;Randomized Multicenter Trial of Cytosine Arabinoside With Mitoxantrone or Daunorubicin in Previously Untreated Adult Patients With Acute Nonlymphocytic Leukemia (ANLL). Lederle Cooperative Group,&quot; <i>Leukemia</i>, 1990, 4(3):177-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/2179638/pubmed\" target=\"_blank\" id=\"2179638\">2179638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper TM, Franklin J, Gerbing RB, et al, &quot;AAML03P1, a Pilot Study of the Safety of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Newly Diagnosed Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group,&quot; <i>Cancer</i>, 2012, 118(3):761-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibson BE, Webb DK, Howman AJ, et al, &quot;Results of a Randomized Trial in Children With Acute Myeloid Leukaemia: Medical Research Council AML12 Trial,&quot; <i>Br J Haematol</i>, 2011, 155(3):366-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/21902686/pubmed\" target=\"_blank\" id=\"21902686\">21902686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health and Human Services (HHS), Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in the healthcare settings 2016. Available at <a href=\"https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf\" target=\"_blank\">https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. <i>J Neurol</i>. 2013;260(5):1202-1214.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/22926165/pubmed\" target=\"_blank\" id=\"22926165\">22926165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeffrey LP, Chairman, National Study Commission on Cytotoxic Exposure. Position Statement. &ldquo;The Handling of Cytotoxic Agents by Women Who Are Pregnant, Attempting to Conceive, or Breast-Feeding,&rdquo; January 12, 1987.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koeller J and Eble M, &ldquo;Mitoxantrone: A Novel Anthracycline Derivative,&rdquo; <i>Clin Pharm</i>, 1988, 7(8):574-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/3048848 /pubmed\" target=\"_blank\" id=\"3048848 \">3048848 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Toxicology Program (NTP) Monograph on Developmental Effects and Pregnancy Outcomes Associated with Cancer Chemotherapy Use during Pregnancy, May 2013. Available at <a href=\"http://ntp.niehs.nih.gov/pubhealth/hat/noms/chemo/index.html\" target=\"_blank\">http://ntp.niehs.nih.gov/pubhealth/hat/noms/chemo/index.html</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Novantrone (mitoxantrone) [prescribing information]. Rockland, MA: EMD Serono, Inc; May 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ortega JJ, Madero L, Mart&iacute;n G, et al, &quot;Treatment With All-trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group,&quot; <i>J Clin Oncol</i>, 2005, 23(30):7632-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/16234524/pubmed\" target=\"_blank\" id=\"16234524\">16234524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker C, Waters R, Leighton C, et al, &quot;Effect of Mitoxantrone on Outcome of Children With First Relapse of Acute Lymphoblastic Leukaemia (ALL R3): An Open-Label Randomised Trial,&quot; <i>Lancet</i>, 2010, 376(9757):2009-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/21131038/pubmed\" target=\"_blank\" id=\"21131038\">21131038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24 Suppl 6:vi160-167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/23813932 /pubmed\" target=\"_blank\" id=\"23813932 \">23813932 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perel Y, Auvrignon A, Leblanc T, et al, &quot;Impact of Addition of Maintenance Therapy to Intensive Induction and Consolidation Chemotherapy for Childhood Acute Myeloblastic Leukemia: Results of a Prospective Randomized Trial, LAME 89/91. Leuc&aacute;mie Aiq&uuml;e My&eacute;lo&iuml;de Enfant,&quot; <i>J Clin Oncol</i>, 2002, 20(12):2774-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/12065553/pubmed\" target=\"_blank\" id=\"12065553\">12065553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(Suppl 7):vii167-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pratt CB, Vietti TJ, Etcubanas E, et al, &ldquo;Novantrone&reg; for Childhood Malignant Solid Tumors. A Pediatric Oncology Group Phase II Study,&rdquo; <i>Invest New Drugs</i>, 1986, 4(1):43-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/3700039 /pubmed\" target=\"_blank\" id=\"3700039 \">3700039 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanz MA, Mart&iacute;n G, Gonz&aacute;lez M, et al, &quot;Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All-trans-retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group,&quot; <i>Blood</i>, 2004, 103(4):1237-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/14576047/pubmed\" target=\"_blank\" id=\"14576047\">14576047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens RF, Hann IM, Wheatley K, et al, &ldquo;Marked Improvements in Outcome With Chemotherapy Alone in Paediatric Acute Myeloid Leukemia: Results of the United Kingdom Medical Research Council's 10th AML Trial. MRC Childhood Leukaemia Working Party,&rdquo; <i>Br J Haematol</i>, 1998, 101(1):130-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/9576193/pubmed\" target=\"_blank\" id=\"9576193\">9576193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wells RJ, Adams MT, Alonzo TA, et al, &ldquo;Mitoxantrone and Cytarabine Induction, High-Dose Cytarabine, and Etoposide Intensification for Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia: Children's Cancer Group Study 2951,&rdquo; <i>J Clin Oncol</i>, 2003, 21(15):2940-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-pediatric-drug-information/abstract-text/12885813/pubmed\" target=\"_blank\" id=\"12885813\">12885813</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12617 Version 135.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709094\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F197570\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048715\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048707\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F197544\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F197529\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F13934999\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048719\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132772\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F197562\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048718\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F197627\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F197623\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F197550\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F197533\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F197613\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F197538\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F197540\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F197553\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048714\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F197532\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F197549\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323431\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F197555\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12617|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mitoxantrone-drug-information\" class=\"drug drug_general\">Mitoxantrone: Drug information</a></li><li><a href=\"topic.htm?path=mitoxantrone-patient-drug-information\" class=\"drug drug_patient\">Mitoxantrone: Patient drug information</a></li></ul></div></div>","javascript":null}